OS THERAPIES INC (OSTX) Stock Price & Overview
NYSEARCA:OSTX • US68764Y2072
Current stock price
The current stock price of OSTX is 1.36 USD. Today OSTX is down by 0%. In the past month the price decreased by -9.93%. In the past year, price decreased by -2.86%.
OSTX Key Statistics
- Market Cap
- 47.886M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.88
- Dividend Yield
- N/A
OSTX Stock Performance
OSTX Stock Chart
OSTX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to OSTX. When comparing the yearly performance of all stocks, OSTX is a bad performer in the overall market: 66.81% of all stocks are doing better.
OSTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OSTX. While OSTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
OSTX Earnings
OSTX Forecast & Estimates
10 analysts have analysed OSTX and the average price target is 13.01 USD. This implies a price increase of 856.25% is expected in the next year compared to the current price of 1.36.
For the next year, analysts expect an EPS growth of 35.31% and a revenue growth -100% for OSTX
OSTX Groups
Sector & Classification
OSTX Financial Highlights
Over the last trailing twelve months OSTX reported a non-GAAP Earnings per Share(EPS) of -0.88. The EPS decreased by -174.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -226.24% | ||
| ROE | -430.26% | ||
| Debt/Equity | 0 |
OSTX Ownership
OSTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.03 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OSTX
Company Profile
OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
Company Info
IPO: 2024-08-01
OS THERAPIES INC
15825 Shady Grove Road, Suite 135
Rockville MARYLAND US
Employees: 4
Phone: 14102977793
OS THERAPIES INC / OSTX FAQ
Can you describe the business of OS THERAPIES INC?
OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
Can you provide the latest stock price for OS THERAPIES INC?
The current stock price of OSTX is 1.36 USD.
What is the dividend status of OS THERAPIES INC?
OSTX does not pay a dividend.
What is the ChartMill rating of OS THERAPIES INC stock?
OSTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of OS THERAPIES INC (OSTX)?
OS THERAPIES INC (OSTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.88).
What is the market capitalization of OSTX stock?
OS THERAPIES INC (OSTX) has a market capitalization of 47.89M USD. This makes OSTX a Nano Cap stock.
What is the outstanding short interest for OS THERAPIES INC?
The outstanding short interest for OS THERAPIES INC (OSTX) is 5.1% of its float.